IDH2 clonal hematopoiesis and IKAROS loss cooperate in a B-ALL subtype after lenalidomide therapy for multiple myeloma.

IDH2 mutations and IKAROS loss define a distinct subtype of lenalidomide-associated B-ALL, with IDH2 R140Q mutations enriched 23% in this condition.

• Why it matters: Understanding the molecular mechanisms behind secondary B-ALL after lenalidomide therapy is crucial for improving patient management and preventing leukemia development in multiple myeloma survivors.
• What they did: The study analyzed 57 patients with lenalidomide-associated B-ALL, identifying three mutational groups, with a focus on IDH2 R140Q mutations and associated genetic features, using sequencing, cell sorting, and methylation profiling.
• The result: Findings suggest lenalidomide promotes expansion of preleukemic IDH2-mutated clones and induces maturation arrest via IKAROS downregulation, establishing IDH2-mutant B-ALL as a distinct, overrepresented subtype that develops independently of ongoing therapy.